| Application no. and date | 18707612.0 (espacenet) (Federated) (European Patent Register), 20180216 | | Patent/reg. no. and date | DK/EP 3510034, 20200422 | | Publication date | 20190717 | | Priority no. and date | US 201762460677 P, 20170217, US 201762490881 P, 20170427, US 201762573991 P, 20171018 | | EP pub. no. and date |
EP 3510034 20190717 | | Effective date | | | Applicant/owner | Innate Tumor Immunity, Inc., Route 206 and Province Line Road
Princeton, New Jersey 08543, US | | Applicant ref. no. | V152630DK | | Inventor | GLICK, Gary, 1663 Snowberry Ridge Road
Ann Arbor, MI 48103, US,
O'MALLEY, Daniel, c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, New Jersey 08543, US,
OLHAVA, Edward James, 11 Scarsdale Road
Newton, MA 02460, US,
GHOSH, Shomir, 134 Sewall Anebue, Unit 3
Brookine, MA 02446, US,
ROUSH, William R., 250 Beach Road Apt. 207
Tequesta, FL 33469, US | | Representative | Marks & Clerk LLP, 44 rue de la Vallée
BP 1775
L-1017 Luxembourg, LU | | Opponent | | | IPC Class | A61K 31/437 (2006.01) , A61P 35/00 (2006.01) , A61P 37/00 (2006.01) , C07D 471/04 (2006.01) | | Title | SUBSTITUEREDE IMIDAZO-QUINOLINER SOM NLRP3-MODULATORER | | Int. application no. | US2018018484 | | Int. publication no. | WO2018152396 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
